Ucb Biopharma Sprl

Ucbbiopharma Srl

Ucb Pharma, S.a.

Shirley Jane Peters

David Paul Humphreys

Paul Edward Stephens

Ralph Adams

Katharine Lacy Cain

James Heads

Bryan John Smith

Robert Anthony Griffin

Farnaz Fallah-Arani

The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a C1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the C1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.

Antibodies of the class IGG4

The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.

Multimeric Fc proteins

The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.

Sequence symmetric modified IgG4 bispecific antibodies

Sequence symmetric modified IGG4 bispecific antibodies

The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has:

Sequence asymmetric modified IgG4 bispecific antibodies

The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.

Growing community of inventors

Slough, United Kingdom

Shirley Jane Peters